There is not a lot of information about primary medication nonadherence, but it could have a huge impact on patients, as discussed by a speaker at the Academy of Managed Care Pharmacy Nexus 2015 meeting.
There is not a lot of information about primary medication nonadherence (PMN), but it could have a huge impact on patients, as discussed by a speaker at the Academy of Managed Care Pharmacy Nexus 2015 meeting, held in Orlando, Florida, October 26-29.
PMN is when a new prescription is written for a medication or for a medication a patient has received before and a certain amount of time passes and the patient fails to pick up the medication during that time period, explained Rebekah Hanson, PharmD, BCPS, BCACP, clinical pharmacist at the University of Illinois at Chicago.
“When you think about the potential impact this could have on patients, if the patient doesn’t start on medication … well, the outcome is going to be very poor in those circumstances,” Dr Hanson said.
Literature has put PMN at anywhere from 5% to 30% of patients, but it is really underrepresented in the literature and there is more information on secondary medication nonadherence (SMN). SMN is likely easier to measure since it’s a matter of persistency, taking the medication on time, etc, she said.
The most common way of identifying PMN is by running e-prescribing data and claims data. There are some efforts to look at orders entered into electronic medical records at the point of entry and then the pick up data at the pharmacy, but there are limitations including: some prescriptions are still written; there are technical glitches; some patients receive samples, which means there is no way to know they started on therapy; some patients pay in cash; and it may be a duplicate prescriptions.
According to Dr Hanson, there are also a number of reasons for PMN:
There are also issues that are specific to specialty pharmacy, which hasn’t really been studied, but there have been studies about why patients might delay treatment:
There are interventions that can be used and the earlier they are initiated the better the outcome, Dr Hanson said. Although these interventions haven’t been studied in specialty pharmacy, she said that many specialty pharmacy services already implement interventions like postcard reminders, telephone reminders, and automated outreach as standard care.
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More